Klinische Pharmakologie von Heparinen

J. Harenberg

doi:10.1055/s-0038-1660310

Hämostaseologie, Table of Contents

Hamostaseologie 1992; 12(01): 023-036
DOI: 10.1055/s-0038-1660310

Übersichtsarbeit/Review Articles

Schattauer GmbH

Klinische Pharmakologie von Heparinen

J. Harenberg

¹1. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg (Direktor: Prof. Dr. D. L. Heene)

› Author Affiliations

Abstract

Zusammenfassung

Ziel klinisch pharmakologischer Studien von Heparinen sind die Analysen der Bioverfügbarkeit und des Metabolismus. Die Untersuchungen erstrecken sich zum einen auf nicht modifizierte und zum anderen auf modifizierte Heparine und verwandte Substanzen. Neue Nachweisverfahren haben die Bedeutung der Hemmung der Faktor-Xa-Aktivität, des Feed-back loop und der Freisetzung des Extrinsic pathway inhibitor (jetzt: Tissue factor pathway inhibitor) herausgestellt. Untersuchungen zur Neutralisation mit Protaminchlorid legen eine Freisetzung von Mukopolysacchariden durch Heparine im Körper nahe. Chemische Modifikationen von Heparinen und verwandten Substanzen geben eine Aussicht auf bessere Nachweisverfahren, alternative Applikationsformen, spezifischere Wirkungen und neue Anwendungsgebiete.

Schlüsselwörter

Heparin - fraktionierte Heparine - Gerinnung - Fibrinolyse

Key words

Heparin - fractionated heparins - blood coagulation - fibrinolysis

Full Text

References

LITERATUR
1 McLean J. The thromboplastic action of cephalin. Am J Physiol 1916; 41: 250-7.
2 Howell WH, Holt E. Two new fractions in blood coagulation. Heparin and proantithrombin. Am J Physiol 1918; 47: 328-41.
3 Harenberg J, de Vries JX. Characterization of heparins by high performance size exclusion liquid chromatography. J Chromatogr 1983; 261: 287-92.
4 Barrowcliffe TW, Johnson A, Eggleton CA, Kemball-Cook G, Thomas DP. Anticoagulant activities of high and low-molecular-weight heparin fractions. Br J Haematol 1979; 41: 573-82.
5 Eggleton CA, Barrowcliffe TW, Merton RE, Thomas DP. In vitro and in vivo studies of the anti Xa activity of heparin. Thromb Res 1981; 24: 319-28.
6 Lane EA, Mac Gregor IR, Michalski R, Kakkar VV. Anticoagulant activities of four unfractionated und fractionated heparins. Thromb Res 1978; 12: 237-46.
7 Barrowcliffe TW, Curtis AD, Johnson EA, Thomas DR. An International Standard for low molecular weight heparin. Thromb Haemostas 1988; 60: 1-7.
8 Holmer E. Anticoagulant properties of heparin and heparin fractions. Scand J Haematol 1980; 24 (Suppl 35): 25-34.
9 Griffith MJ. Covalent modification of human alpha-thrombin with pyridoxal 5phosphate. J Biol Chem 1979; 254: 3401-6.
10 Gitel SN. Evidence of a catalytic role of heparin in coagulation reactions. In: Bradshaw RA, Wessler ST. (eds). Heparin, Structure, Function and Clinical Implications. New York, London: Plenum Press; 1975: 243-54.
11 Casu B, Oreste P, Torri G, Zopetti G, Choay J, Lormeau JC, Petitou M. The structure of heparin oligosaccharide fragments with high antifactor X a activity containing the minimal antithrombin Ill-binding sequence. Biochem J 1981; 197: 599-609.
12 Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III. Biochem Biophys Res Commun 1983; 116: 492-9.
13 Hobbelen PMJ, Van Dinther TG, Vogel GMT, van Boeckel CAA. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemostas 1990; 63: 265-70.
14 Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-98.
15 Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-7.
16 Hurst RE, Dedem G, Settine M. Biophysical characteristics of anionic density-fractionated mucosal heparins in relation to potencies in anticoagulant and thrombininhibition assays. Thromb Res 1981; 22: 633-43.
17 Jaques LB, Ricker AG. The relationship between heparin dosage and clotting time. Blood 1948; 03: 1197-212.
18 Olssen P, Logergren H, Ek S. The elimination from plasma of intravenous heparin. Acta Med Scand 1963; 173: 619-30.
19 Olssen P, William-Olsson G, Lagergren H. The elimination rate of heparin from plasma on normothermic and hypothermic dogs. Acta Chir Scand Suppl 1959; 245: 359-62.
20 Perry MO, Horton J. Kinetics of heparin administration. Arch Sur g 1976; 111: 403-9.
21 Harris PA, Harris KL. Kinetics of heparin removal from circulation of the minipig. J Pharm Sci 1974; 63: 138-9.
22 Sue TK, Jaques LB, Yell J. A strain difference in anticoagulant response to subcutaneous administration of heparin in mice. Thromb Res 1977; 12: 5-13.
23 Jorpes JE. The chemistry of heparin. Biochemistry 1935; 29: 1817-32.
24 Estes JW, Pelikan EW, Krüger-Thiemer E. A retrospective study of the pharmacokinetics of heparin. Clin Pharmacol Ther 1969; 10: 329-37.
25 Zöllner N, Kaiser W. Über Verteilungsraum und Halbwertszeit von intravenös injiziertem Heparin. Res Exp Med 1972; 158: 89-94.
26 Harenberg J, Stehle G, Augustin J, Zimmermann R. Comparative human pharmacology of low molecular weight heparins. Sem Thromb Hemostas 1989; 15: 414-23.
27 Me Avoy TJ. Pharmacokinetics, modeling of heparin and its clinical implications. J Pharm Biopharm 1979; 07: 331-54.
28 Fareed J, Kumar A, Walenga JM, Emanuele RM, Wiliamson K, Hoppensteadt D. Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv Rev Fr Hematol 1984; 26: 267-75.
29 Ceustermans R, Hoylaerts M, de Mol M, Collen D. Preparation, characterization, and turnover properties of heparin-antithrombin III complexes stabilized by covalent bonds. J Biol Chem 1982; 257: 3401-8.
30 Hoylaerts M, Holmer E, de Mol M, Collen D. Covalent complexes between low molecular weight heparin fragments and antithrombin III-inhibition kinetics and turnover parameters. Thromb Haemostas 1983; 49: 109-15.
31 Boneu B, Buchanan MR, Caranobe C, Gabaig AM, Bupouy D, Sie P, Hirsh J. The disappearance of a low molecular weight heparin fraction (CY 215) differs from standard heparin in rabbits. Thromb Res 1987; 46: 845-53.
32 Briant L, Caranobe C, Saivin S, Sié P, Bayrou B, Houin G, Boneu B. Unfractionated heparin and CY 216: Pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemostas 1989; 61: 348-53.
33 Emanuele RM, Fareed J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987; 48: 591-6.
34 Palm M, Wu H, Mattsson C, Ansari A. Pharmacokinetic properties of size-homogeneous heparin oligosaccharides. Thromb Res 1990; 59: 799-805.
35 Harenberg J. Pharmacology of low molecular weight heparins. Sem Thromb Haemostas 1990; 16 (Suppl): 12-8.
36 Dawes J, Pepper DS. Catabolism of lowdose heparin in man. Thromb Res 1979; 14: 845-60.
37 Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood. Thromb Haemostas 1988; 60: 377-81.
38 Black J, Nagle CJ, Strachan CJL. Prophylactic low-dose heparin by jet injection. Br Med J 1978; 03: 95-6.
39 Harenberg J, Arleth D, Köppern K, Matthes K, Zimmermann R. Subkutane Applikation von Heparin mit einem Injektor. Dtsch Med Wochenschr 1982; 107: 497-500.
40 Möller H. Pharmazeutische Qualität von parenteralen Heparin-Fertigarzneimitteln. Pharm Z 1982; 17: 933-5.
41 Nader HB, Takahashi HK, Guimaraes JA, Dietrich CP, Bianchini P, Ozima B. Heterogeneity of heparin: characterization of one hundred components with different anticoagulant activities by a combination of electrophoretic and affinity chromatography methods. Int J Biol Macromol 1981; 03: 356-60.
42 Hurst RE, Settine JM, Poon MC, Lurie A. Heterogeneity in the composition of commercial heparins: comparison of anticoagulant activities and biochemical compositions of anionic density-fractionated heparins. Thromb Res 1982; 25: 255-65.
43 Shen LL, Barlow GH, Hollemann WH. Differential activities of heparins in human plasma and in sheep plasma. Effects of heparin molecular sizes and sources. Thromb Res 1978; 13: 671-9.
44 Aiach M, Kher A, Michaud A, Mardiguian J, Trillou M, Leclerc M. Anticoagulant activity of beef and hog mucosal heparins. Thromb Res 1979; 14: 167-77.
45 Whitehead MI, MacCarthy TGH. A comparative trial of subcutaneous sodium and calcium heparin as assessed by local haematoma formation and pain. In: Kakkar VV, Thomas DP. (eds). Heparin. Chemistry and Clinical Usage. London, New York, San Francisco; Academic Press; 1976: 361-6.
46 Cade JF, Andrews JT, Stubbs AE. Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Aust N Z J Med 1982; 12: 501-4.
47 Thomas DP, Sagar S, Stamatakis JD, Mafei FHA, ERdi A, Kakkar VV. Plasma heparin levels after administration of calcium and sodium salts of heparin. Thromb Res 1976; 09: 241-8.
48 Johnson EA, Kirwood TBL, Stirling Y, Perezu-Requejo JL, Ingram GIC, Bangham DR, Brozovic M. Four heparin preparations : anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemostas 1976; 35: 586-91.
49 Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J. Anticoagulant and lipolytic effects of a low-molecular-weight heparin fraction. Thromb Res 1985; 39: 683-92.
50 Merton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thromb Haemostas 1987; 58: 839-46.
51 Harenberg J, Wiirzner B, Zimmermann R, Schettler G. Bioavailability and antagonization of the low-molecular-weight heparin CY 216 in man. Thromb Res 1986; 44: 549-55.
52 Rostin M, Montastruc JL, Houin G, D’Azemar P, Bayrou B, Boneu B. Pharmacodynamics of CY 216 in healthy volunteers : inter-individual variations. Fundam Clin Pharmacol 1990; 04: 17-23.
53 Hobbelen PM, Vogel GM, Meuleman DG. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats. Thromb Res 1987; 48: 549-58.
54 Hoppensteadt D, Walenga JM, Fareed J. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparin sulfate and heparin. Thromb Res 1990; 60: 191-200.
55 Bang CJ, Berstad A, Talstad I. Gastric mucosal bleeding after unfractionated and low molecular weight heparin in rats. Scand J Gastroenterol 1990; 25: 379-82.
56 Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers. Thromb Haemostas 1989; 61: 357-62.
57 Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988; 28: 609-18.
58 Astrup P. On the determination of heparin in blood plasma and urine. Acta Pharmacol 1947; 03: 165-78.
59 Jaques LB, Napke E, Levy SW. The metachromatic activity of urine following the injection of heparin. Circ Res 1953; 01: 321-30.
60 Me BMAllister, Demis DJ. Heparin metabolism isolation and characterization of uroheparin. Nature 1966; 212: 293-4.
61 Copley AL, Schnedorf JG. The rate of excretion of heparin in the urine following its intravenous injection in the anesthetized dog. Am J Physiol 1941; 133: 562-5.
62 Marbert R, Winterstein A. Probleme der Blutgerinnung über die Ausscheidung des Heparins im Urin. Helv Physiol Pharmac Acta 1951; 09: 24-32.
63 Shanberge JN, Gruhl M, Kitani T, Ambeganonkar S, Kabayashi J, Nakagawa M, Lenter D. Fractionated tritium-labelled heparin studied in vitro and in vivo. Thromb Res 1978; 13: 767-83.
64 Bjornsson TD, Levy G. Pharmacokinetics of Heparin. I. Studies of dose dependence in rats. J Pharmacol Exp Ther 1979; 210: 237-42.
65 Watanabe J, Hori K, Iwamoto K, Ozeki S. Disposition of tritium-labelled heparin in rats. J Pharm Dyn 1982; 05: 627-37.
66 Stau T, Metz J, Taugner R. Exogenous 35S-labeled heparin: organ distribution and metabolism. Naunyn Schmiedebergs Arch Pharmacol 1973; 280: 93-102.
67 Piper J. The fate of heparin in rabbits intravenous injection. Acta Pharmacol 1947; 03: 373-84.
68 Day M, Green JP, Robinson JD. Disposition of [35S]-heparin in the rat. Br J Pharmacol 1962; 18: 625-9.
69 Losito R, Gattiker H, Bilodeau G. Heparin excretion in intact and hepatectomized rats. Thromb Haemostas 1981; 45: 146-9.
70 Guizzardi S, Mastacchi R, Govoni P, Milani MR, Barbanti M, Ruggeri A. Pharmacokinetics and organ distribution in rats of a low molecular weight heparin. Arzneimittelforschung 1987; 37: 1281-3.
71 Eiber HB, Danishefsky I, Borrelli FJ. Studies made with radioactive heparin in humans. Angiology 1960; 11: 40-3.
72 Mombelli G, Schaedelin J, Beck EA. Pharmakokinetik von Heparin nach einmaliger intravenöser oder subkutaner Injektion. Schweiz Med Wochenschr 1977; 107: 810-5.
73 Esquerre JP, Boneu B, Guiraud R. Kinetics of technetium-labeled heparin in thromboembolism: Preliminary report. Int J Nucl Med Biol 1979; 06: 215-20.
74 Teien AN, Bjornson J. Heparin elimination in uremic patients on haemo-dialysis. Scand J Haematol 1976; 17: 19-25.
75 Andrassy K, Salzmann W, Saggau W, Storch H, Ritz E. Is more heparin necessary for low-dose heparin prophylaxis in uremic patients?. Thromb Haemostas 1981; 46: 740-2.
76 Teien AN. Heparin elimination in patients with liver cirrhosis. Thromb Haemostas 1977; 38: 701-5.
77 Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691-5.
78 Simon TL, Hyers TM, Gaston JP, Harker LA. Heparin pharmacokinetics: increased requirements in pulmonary embolism. Br J Haematol 1978; 39: 111-20.
79 Mungall D, Raskob G, Coleman R, Rosenbloom D, Ludden T, Hull R. Pharmacokinetics and dynamics of heparin in patients with proximal vein thrombosis. J Clin Pharmacol 1989; 29: 896-900.
80 Ostergaard PB, Nilsson B, Bergqvist D, Hedner U, Pedersen PC. The effect of low molecular weight heparin on experimental thrombosis and haemostasis the influence of production method. Thromb Res 1987; 45: 739-49.
81 Psuja P. Kinetics of radiolabelled (99mTc) heparin and low molecular weight heparin fraction CY 216, CY 222 in patients with uncomplicated myocardial infarction. Folia Haematol Leipz 1988; 115: 661-8.
82 Andrew M, Cade J, Buchanan MR, Cerskus AL, Jefferis A, Towell M, Hirsh J. Low molecular weight heparin does not cross the placenta. Thromb Haemostas 1983; 50: 225 (Abstract).
83 Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemostas 1987; 57: 234.
84 Mahadoo J, Hiebert L, Jaques LD. Vascular sequestration of heparin. Thromb Res 1977; 12: 79-90.
85 Hiebert LM, Jaques LB. The observation of heparin on endothelium after injection. Thromb Res 1976; 08: 195-204.
86 Glimelius B, Bush C, Höök M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res 1978; 12: 773-82.
87 Fabian I, Bleiberg I, Aronson M. Desulphation of heparin by mice and guinea pig leucocytes. Biochim Biophys Acta 1976; 437: 122-8.
88 Bleiberg I, Fabian I, Aronson M. Mode of binding and internalization into mouse macrophages of heparin complexed with polycations. Biochim Biophys Acta 1981; 674: 345-53.
89 Bleiberg I, MacGregor I, Aronson M. Heparin receptors on mouse macrophages. Thromb Res 1983; 29: 52-61.
90 Fabian I, Bleiberg I, Aronson M. Increased uptake and desulphation of heparin by mouse macrophages in the presence of polycations. Biochim Biophys Acta 1978; 544: 69-76.
91 Van Ryn-Mc Kenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemostas 1990; 62: 271-4.
92 Vannucchi S, Pasquali F, Porciatti F, Chiarugi V, Magnelli L, Bianchini P. Binding, internalization and degradation of heparin and heparin fragments by cultured endothelial cells. Thromb Res 1988; 49: 373-83.
93 Bauer G, Boström H, Jorpes E, Kallner L. Intramuscular administration of heparin. Acta Med Scand 1950; 136: 188-98.
94 Rapaport SJ, Ames SB. Clotting factor assays on plasma from patients receiving intramuscular or subcutaneous heparin. Am J Med Sci 1957; 29: 678-86.
95 Busch H, Thürmann D. Untersuchungen über die Depotwirkung von intramuskulär und subkutan injizierbaren Heparinen. Med Welt 1971; 22: 1760-1.
96 Wegmann R, Garraud R. Le problème de l’absorption cutanée de l’héparine. Presse Méd 1961; 69: 898-902.
97 Ekre HPT, Fjellner B, Hägermark Ö. Inhibition of complement dependent experimental inflammation in human skin by different heparin fractions. Int J Immunopharmacol 1986; 08: 277-86.
98 Ekre HPT. Inhibition of human and guinea pig complement by heparin fractions differing in affinity for antithrombin III or in average molecular weight. Int J Immunopharmacol 1985; 07: 277-80.
99 Stüttgen G, Panse P, Bauer E. Permeation of the human skin by heparin and mucopolysaccharide polysulfuric acid ester. Drug Res 1990; 40: 484-9.
100 Stüttgen G, Panse P, Bauer E. Heparin and mucopolysaccharide polysulfuric acid ester permeate human skin. Z Hautkr 1989; 64 756, 761-62, 765.
101 Bergqvist D, Brunkwall J, Jensen N, Persson NH. Treatment of superficial thrombophlebitis. A comparative trial between placebo, hirudoid cream and piroxicam gel. Ann Chir Gynaecol 1990; 79: 92-6.
102 Nader HB, Tersariol IL, Dietrich EP. Structural requirements of heparin disaccharides responsible for hemorrhage: reversion of the antihemostatic effect by ATP. FASEB J 1989; 03: 2420-4.
103 Litwins J, Vorzimer JJ, Sussman LN, Applezweig N, Etess AD. Sublingual administration of heparin. Proc Soc Exp Biol Med 1951; 77: 325-6.
104 Me Devitt E, Huebner RD, Wright IS. Ineffectiveness of heparin by sublingual administration. J Am Med Ass 1952; 148: 1123-4.
105 Ueno M, Nakasaki T, Horikoshi I, Sakuragawa N. Oral administration of liposomally entrapped heparin to beagle dogs. Chem Pharm Bull 1982; 30: 2245-7.
106 Lasker SE. Low-molecular-weight derivative of heparin that is orally active in mice. In: Bradshaw RA, Wessler S. (eds). Heparin Structure, Function, and Clinical Implications. New York, London: Plenum Press; 1975: 119-27.
107 Dryjski M, Schneider DE, Mojaverian P, Kuo BS, Bjornsson TD. Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations. Br J Clin Pharmacol 1989; 28: 188-92.
108 dal Pozzo AD, Acquasaliente M, Geron MR. New heparin complexes active by intestinal absorption: I-multiple ion pairs with basic organic compounds. Thromb Res 1989; 56: 119-24.
109 Wright CJ, Mahadoo J, Jaques LB. Anticoagulant activity and operative blood loss after intrapulmonary heparin. Br J Surg 1979; 66: 844-7.
110 Mahadoo J, Wright CJ, Jaques LB. Effects of intrapulmonary heparin on lipoprotein lipase activity in mice. Atherosclerosis 1981; 38: 197-202.
111 Jaques LB, Mahadoo J, Kavanagh LW. Intrapulmonary heparin. Lancet 1976; II: 1157-61.
112 Mahadoo J, Hines JG, Jaques LB. Effects of long-term treatment of mice with intrapulmonary heparin. Drug Res 1981; 31: 976-8.
113 Kaulla KN, Me Donald ST, Taylor GH. The effect of heparin on fibrinolysis. J Lab Clin Med 1956; 48: 952-6.
114 Markwardt F, Klöcking HP. Heparininduced release of plasminogen activator. Haemostasis 1977; 06: 370-4.
115 Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh NA, Gaffney PJ. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-24.
116 Harenberg J, Walter E, Weber E. Die intraindividuelle Streuung der fibrinolytisehen Aktivität bei Probanden. Klin Wochenschr 1978; 56: 445-8.
117 Fareed J, Walenga JM, Hoppensteadt DA, Messmore HL. Studies on the profibrinolytic actions of heparin and its fractions. Semin Thromb Hemost 1985; 11: 199-206.
118 Stassen JM, Juhan-Vague I, Alessi MC, de Cook F, Collen D. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator. Thromb Haemostas 1987; 58: 947-51.
119 Porta R, Pescador R, Niada R, Diamantini G, Fedeli GF, Mantovani M, Prino G. Profibrinolytic activities of chemically modified heparins with very low anticoagulant activities. Thromb Res 1989; 53: 435-43.
120 Doutremepuich D, Deharo E, Doutremepuich F, Lalanne MC, Toulemonde F. Kinetic study of tPA release induced by heparin and heparin fragment. Thromb Res 1989; 53: 615-21.
121 Sorensen JV, Borris LC, Lassen MR, Christiansen HM, Schott P, Olsen AD, Neerstrand HS. Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis influence of prophylaxis with a low molecular weight heparin. Thromb Res 1990; 59: 131-8.
122 Eriksson E, Wollter IM, Christenson B, Stigendal L, Risberg B. Heparin and fibrinolysis comparison of subcutaneous administration of unfractionated and low molecular weight heparin. Thromb Haemostas 1988; 59: 284-8.
123 Grimaudo V, Omri A, Kruithof EK, Hauert J, Bachmann F. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination. Thromb Haemostas 1988; 59: 388-91.
124 Agnelli G, Levi M, Cosmi B, ten Cate JW, Nenci GG. Additive effect of dDAVP and standard heparin in increasing plasma t- PA. Thromb Haemostas 1989; 61: 507-10.
125 Rapaport RS, Ronchetti-Blume M, Vogel RL, Hung PP. Heparin potentiates endothelial cell growth factor stimulation of plasminogen activator synthesis by diploid human lung fibroblasts. Thromb Haemostas 1988; 59: 514-22.
126 Fry ET, Sobel BE. Lack of interference by heparin with thrombolysis or binding of tissue-type plasminogen activator to thrombi. Blood 1988; 71: 1347-52.
127 Arnesen H, Engebretsen LF, Ugland OM, Seljeflot I, Kierulf P. Increased fibrinolytic activity after surgery induced by low dose heparin. Thromb Res 1987; 45: 553-9.
128 Gorog P, Ridler CD, Kovacs IB. Heparin inhibits spontaneous thrombolysis and the thrombolytic effect of both streptokinase and tissue-type plasminogen activator. An in vitro study of the dislodgement of platelet-rich thrombi formed from native blood. J Intern Med 1990; 227: 125-32.
129 Millot F, Etienne J, Aiach M, Meyniel D, Brault D, Pieron R, Lamelle P. Effet d’un dérivé de l’héparine de faible poids moléculaire sur la libération d’une activité lipolytique dans la circulation sanguine. C R Acad Sc 1982; 295: 771-6.
130 Harenberg J, Stehle G, Dempfle CE, von Hodenberg E, Heene DL. Beeinflussung der Blutgerinnung und der Lipasen durch das niedermolekulare Heparin CY 216. Ärztl Lab 1989; 35: 73-9.
131 Persson E, Nordenström J, Nilsson-Ehle P. Plasma kinetics of lipoprotein lipase and hepatic lipase activities induced by heparin and a low-molecular weight heparin by fragment. Scand J Clin Lab Invest 1987; 47: 151-6.
132 Persson E, Nordenström J, Nilsson-Ehle P, Hagenfeld L. Lipolytic and anticoagulant activities of a low-molecular weight fragment of heparin. Eur J Clin Invest 1985; 15: 215-20.
133 Williams SP, Barrowcliffe TW. The effects of postheparin plasma lipases on anti-Xa clotting activity. Thromb Res 1985; 37: 371-8.
134 Gray E, Bengtsson-Olivecrona G, Olivecrona T, Barrowcliffe TW. The anti-Xa activity of human hepatic triglyceride lipase (HTGL). J Lab Clin Med 1987; 109: 653-9.
135 Harenberg J, Augustin J. Antithrombotic action of hepatic triglyceride lipase - fact or fiction. Thromb Haemostas 1987; 57: 241.
136 Pescador R, Porta R, Niada R, Diamantini G, Fedeli G, Mantovàni M. The anticoagulant lipase-releasing and lipoprotein lipase-releasing activities of several natural and chemically modified heparins differ. Biochem Pharmacol 1987; 36: 253-7.
137 Broze GJ, Miletich JP. Characterization of the inhibition of tissue factor in serum. Blood 1987; 69: 150-5.
138 Schmidt M, Barrowcliffe TW, Gray E, Watton J, Harenberg J. Anti-Xa clotting activities in different hepatic-triglyceride lipase preparations from post-heparin plasma. Thromb Res 1991; 63: 503-8.
139 Gemmell CH, Broze GJ, Turitto VT, Nemerson Y. Utilization of a continuous flow reactor to study the lipoprotein-associated coagulation inhibitor (LACI) that inhibits tissue factor. Blood 1990; 76: 2266-71.
140 Lindahl AK, Abildgaard U, Stokke G. Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990; 59: 651-6.
141 Michalski R, Lane DA, Pepper DS, Kakkar VV. Neutralization of heparin in plasma by platelet factor IV and protamine sulphate. Br J Haematol 1978; 38: 561-71.
142 Fabris F, Fussi F, Casonato A, Visentin L, Rand M, Smith MR, Girolami A. Normal and low molecular weight heparin interaction with human platelets. Eur J Clin Invest 1983; 13: 135-9.
143 Mastacchi R, Stanzani L, Barbanti M, Montecci L, Bianchini P. Interaction of heparin and heparin fractions with human platelets. Thromb Res 1982; 28: 275-80.
144 Handin RI, Cohen HJ. Purification and binding properties of human platelet factor 4. J Biol Chem 1976; 251: 4273-82.
145 Jorpes JE, Edman P, Thaning T. Neutralisation of action of heparin by protamine. Lancet 1939; II: 975-6.
146 Holmer E, Söderström G. Neutralization of unfractionated heparin and a low molecular weight (LMW) heparin fragment by protamine. Thromb Haemostas 1983; 50: 103 (Abstract).
147 Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J. Inhibition of low-molecular-weight heparin by protamine chloride in vivo. Thromb Res 1985; 38: 11-20.
148 Okajma Y, Kayama S, Maeda Y, Urano S, Kitani T, Watada M, Nakagawa M, Ijichi H. Studies on the neutralizing mechanism of antithrombin activity of heparin by protamine. Thromb Res 1981; 24: 21-9.
149 Frick PG, Brögli H. The mechanism of heparin rebound after extracorporal circulation for open cardiac surgery. Surgery 1966; 59: 721-6.
150 Gollub H. Heparin rebound in open heart surgery. Surg Gynecol Obstet 1967; 124: 337-46.
151 Harenberg J, Stehle G, Dempfle CE, von Hodenberg E, Heene DL. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects. Folia Haematol Leipz 1989; 116: 967-80.
152 Harenberg J, Giese C, Knödler A, Zimmermann R, Schettler G. Neutralization of a low molecular weight heparin Kabi 2165 by protamine chloride. Klin Wochenschr 1986; 64: 1171-5.
153 Diness V, Ostergaard PB. Neutralization of a low-molecular-weight heparin (LHN- 1) and conventional heparin by protamine sulfate in rats. Thromb Haemostas 1986; 56: 318-24.
154 Hubbard AR, Jennings CA. Neutralization of heparan sulphate and low-molecular-weight heparin by protamine. Thromb Haemostas 1985; 13: 86-90.
155 Massonnet-Castel S, Pelissier E, Bara L, Terrier E, Abry B, Guibourt P, Swanson J, Jaulmes B, Carpentier A, Samama M. Partial reversal of low-molecular-weight heparin (PK 10169) anti-Xa activity by protamine sulfate: In vitro and in vivo study during cardiac surgery with extracorporal circulation. Haemostasis 1986; 16: 139-45.